1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag

Senzime receives large order from leading California University Hospital System

Uppsala, Sweden, July 20, 2023. Senzime AB (publ), a leader in the field of peri- and post-operative patient monitoring solutions, today announced an initial order from a leading California-based University Hospital System consisting of 70 TetraGraph monitors to be installed over a 9-month period. Initial order value amounts to approximately SEK 1.5 million and the monitors are expected to generate annual recurring revenues in excess of SEK 3 million per year in full use. The order was secured following an extensive clinical evaluation process.

“This is yet another major win for us in the US market and we continue to develop our market position as the leading provider of neuromuscular monitoring solutions. The order is the result of the work of our dedicated team, our commitment to patient safety and our solutions that are perfectly in-line with the new clinical guidelines”, comments Philip Siberg, CEO of Senzime.

The TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and that meets the new clinical guidelines published by ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care). Since market introduction in 2019, the TetraGraph has been installed at hundreds of leading hospitals across the globe.

The TetraGraph system is used during surgery to accurately monitor the patient’s level of neuromuscular blockade. This helps anesthesiologists secure the right dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Senzime receives large order from leading California University Hospital System

Datum 2023-07-20, kl 17:00
Källa MFN
Bifogade filer
Senzime receives large order from leading California University Hospital System
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet